史泰德斯制药公司以1200万美元收购桑多兹非洲仿制品组合,扩大其区域足迹和市场领导地位. Strides Pharma acquires Sandoz’s African generics portfolio for $12M, expanding its regional footprint and market leadership.

作为Strides Pharma Science的子公司, Strides Pharma International AG已同意以1200万美元收购桑多斯在撒哈拉以南非洲地区的一系列品牌仿制药产品.该交易预计将于2026年9月30日完成. Strides Pharma International AG, a subsidiary of Strides Pharma Science, has agreed to acquire a portfolio of branded generic pharmaceutical products from Sandoz AG across Sub-Saharan Africa for $12 million, with the deal expected to close by September 30, 2026. 收购涉及加纳,尼日利亚,肯尼亚和10个西非国家, 包括抗感染药品,心血管治疗以及皮肤病疗法等产品, 其中许多产品每年取超过100万美元. The acquisition covers Ghana, Nigeria, Kenya, and 10 West African countries, including brands in anti-infective, cardiovascular, and dermatology therapies, many generating over $1 million annually. 通过内部资源融资的交易预计将增加每股收益,并将使Strides在该地区的业务增长一倍以上,从而加强其市场领导地位. The transaction, funded through internal resources, is projected to be earnings-per-share accretive and will more than double Strides’ presence in the region, strengthening its market leadership. 支持该公司"在非洲为非洲"的战略, 并旨在将Strides定位在销售额方面进入该地区前五名制药企业之列. It supports the company’s “in Africa for Africa” strategy and aims to position Strides among the top five pharmaceutical companies in the region by sales.